Clinical practice guideline for postmenopausal osteoporosis with traditional Chinese medicine
The editorial group of the clinical practice guideline for postmenopausal osteoporosis(PMOP) with traditional Chinese medicine(TCM)(hereinafter referred to as "guideline") is composed of experts specialized in TCM orthopedics, TCM gynecology, clinical epidemiology, etc. The guideline was formulated through registration, collection and selection of clinical issues/outcome indicators, evidence retrieval and screening, preparation of systematic reviews, evaluation of evidence quality, formation of recommendations, drafting, and peer review. The syndromes and treatment of PMOP are elaborated in detail. Specifically, Liuwei Dihuang Pills and Zuogui Pills are recommended for PMOP with Yin deficiency in the liver and kidney, Qing'e Pills for PMOP with kidney deficiency and blood stasis, Yougui Pills and Jingui Shenqi Pills for PMOP with Yang deficiency in the spleen and kidney, and Er'xian Decoction for PMOP with Yin and Yang deficiency in the kidney. In addition, Duhuo Jisheng Decoction can be used to relieve pain. The commonly used Chinese patent medicines include Xianling Gubao Capsules, Qianggu Capsules, Jintiange Capsules, Gushukang Capsules, Hugu Capsules, Jinwu Gutong Capsules, and Guyuling Capsules. Acupuncture and moxibustion are also effective approaches for PMOP. The rehabilitation and daily management were carried out by exercise therapies such as Baduanjin(eight-section brocade), Wuqinxi(five-animal exercises), and Taijiquan(Tai Chi), Chinese medicine diet, health education, and fall prevention. The promotion and application of this guideline will facilitate the implementation of TCM prevention and treatment of PMOP, ensure the quality of life of PMOP patients, provide effective and safe TCM treatment measures for PMOP, and reduce the risk of fracture complications.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
---|---|
Enthalten in: |
Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica - 46(2021), 22 vom: 15. Nov., Seite 5992-5998 |
Sprache: |
Chinesisch |
---|
Beteiligte Personen: |
Xie, Yan-Ming [VerfasserIn] |
---|
Links: |
---|
Themen: |
Drugs, Chinese Herbal |
---|
Anmerkungen: |
Date Completed 27.12.2021 Date Revised 27.12.2021 published: Print Citation Status MEDLINE |
---|
doi: |
10.19540/j.cnki.cjcmm.20210709.501 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM334870941 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM334870941 | ||
003 | DE-627 | ||
005 | 20231225224628.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||chi c | ||
024 | 7 | |a 10.19540/j.cnki.cjcmm.20210709.501 |2 doi | |
028 | 5 | 2 | |a pubmed24n1116.xml |
035 | |a (DE-627)NLM334870941 | ||
035 | |a (NLM)34951191 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a chi | ||
100 | 1 | |a Xie, Yan-Ming |e verfasserin |4 aut | |
245 | 1 | 0 | |a Clinical practice guideline for postmenopausal osteoporosis with traditional Chinese medicine |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 27.12.2021 | ||
500 | |a Date Revised 27.12.2021 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a The editorial group of the clinical practice guideline for postmenopausal osteoporosis(PMOP) with traditional Chinese medicine(TCM)(hereinafter referred to as "guideline") is composed of experts specialized in TCM orthopedics, TCM gynecology, clinical epidemiology, etc. The guideline was formulated through registration, collection and selection of clinical issues/outcome indicators, evidence retrieval and screening, preparation of systematic reviews, evaluation of evidence quality, formation of recommendations, drafting, and peer review. The syndromes and treatment of PMOP are elaborated in detail. Specifically, Liuwei Dihuang Pills and Zuogui Pills are recommended for PMOP with Yin deficiency in the liver and kidney, Qing'e Pills for PMOP with kidney deficiency and blood stasis, Yougui Pills and Jingui Shenqi Pills for PMOP with Yang deficiency in the spleen and kidney, and Er'xian Decoction for PMOP with Yin and Yang deficiency in the kidney. In addition, Duhuo Jisheng Decoction can be used to relieve pain. The commonly used Chinese patent medicines include Xianling Gubao Capsules, Qianggu Capsules, Jintiange Capsules, Gushukang Capsules, Hugu Capsules, Jinwu Gutong Capsules, and Guyuling Capsules. Acupuncture and moxibustion are also effective approaches for PMOP. The rehabilitation and daily management were carried out by exercise therapies such as Baduanjin(eight-section brocade), Wuqinxi(five-animal exercises), and Taijiquan(Tai Chi), Chinese medicine diet, health education, and fall prevention. The promotion and application of this guideline will facilitate the implementation of TCM prevention and treatment of PMOP, ensure the quality of life of PMOP patients, provide effective and safe TCM treatment measures for PMOP, and reduce the risk of fracture complications | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a TCM clinical practice guideline | |
650 | 4 | |a evidence-based guideline | |
650 | 4 | |a postmenopausal osteoporosis | |
650 | 7 | |a Drugs, Chinese Herbal |2 NLM | |
700 | 1 | |a Liu, Huan |e verfasserin |4 aut | |
700 | 1 | |a Jiang, Jun-Jie |e verfasserin |4 aut | |
700 | 1 | |a Wei, Xu |e verfasserin |4 aut | |
700 | 1 | |a Shen, Hao |e verfasserin |4 aut | |
700 | 1 | |a Zhi, Ying-Jie |e verfasserin |4 aut | |
700 | 1 | |a Sun, Jing |e verfasserin |4 aut | |
700 | 1 | |a Li, Jin-Yu |e verfasserin |4 aut | |
700 | 1 | |a Bao, Xiao-Xia |e verfasserin |4 aut | |
700 | 1 | |a Shi, Wei |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Yi-Li |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica |d 1989 |g 46(2021), 22 vom: 15. Nov., Seite 5992-5998 |w (DE-627)NLM012733113 |x 1001-5302 |7 nnns |
773 | 1 | 8 | |g volume:46 |g year:2021 |g number:22 |g day:15 |g month:11 |g pages:5992-5998 |
856 | 4 | 0 | |u http://dx.doi.org/10.19540/j.cnki.cjcmm.20210709.501 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 46 |j 2021 |e 22 |b 15 |c 11 |h 5992-5998 |